ReviewJournal of clinical and experimental hepatology
Immunosuppressive Drugs in Liver Transplant: An Insight.
Review in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Anti-inflammatory and anti-rejection effects of herbal medicine ingredients in organ transplantation: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- T-cell specific antibody induction versus corticosteroid induction immunosuppression for liver transplant recipients: a meta-analysis.Scientific reports · 2023Pooled it
- Tensor-based integration of time-series measurements reveals relationships between underlying disease, early injury, and T cell polarization in liver transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026Article
- Engineering CAR T Cells for Hepatocellular Carcinoma Recurrence after Liver Transplantation.bioRxiv : the preprint server for biology · 2026Article
- Reporting patterns of renal failure associated with immunosuppressant combinations following liver transplantation: a retrospective analysis.Clinical transplantation and research · 2026Article
- Induction of Clinical Operational Tolerance Through Immunosuppression Minimization: Less Is More?Liver international : official journal of the International Association for the Study of the Liver · 2026Review
- Glucagon-like Peptide-1 Receptor Agonists in Liver Transplant Recipients: A Retrospective Cohort Study.Transplantation direct · 2026Article
- Inhibition of LDHA promotes GSDME-dependent pyroptosis by activating RIG-I-like receptor signaling.Apoptosis : an international journal on programmed cell death · 2026Article
- A multifactorial approach to tacrolimus therapeutic drug monitoring in complex liver transplantation: a case report.Frontiers in medicine · 2026Article
- The Differential Effects of Immunosuppressants on Hepatitis E Virus Replication and the Triggered Inflammatory Responses in Macrophages.Journal of viral hepatitis · 2026Article
- COVID-19 risk perception, preventive behaviors, vaccination acceptance and hesitancy, and psychosocial status in liver transplant recipients.Frontiers in public health · 2026Article
- Factors Associated with Candidemia After Living Donor Liver Transplantation: A Case-Control Study.Journal of clinical medicine · 2025Article
- Liver transplantation for homozygous familial hypercholesterolaemia.Current opinion in lipidology · 2025Review
- Polysaccharides derived from alkali-extracted vinegar-bakedJournal of traditional and complementary medicine · 2025Article
- Recurrent drug-induced liver injury in pediatric living donor liver transplantation: a case report.World journal of emergency medicine · 2025Article
- Hepatitis C Direct-Acting Antivirals in the Immunosuppressed Host: Mechanisms, Interactions, and Clinical Outcomes.Viruses · 2025Review
- Review
- Cytopenias in Autoimmune Liver Diseases-A Review.Journal of clinical medicine · 2025Review
- Side Effects of Immunosuppressant Drugs After Liver Transplant.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Update on the Complications and Management of Liver Cirrhosis.Medical sciences (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver transplantation (LT) is the standard of care for end-stage liver failure and hepatocellular carcinoma. Over the years, immunosuppression regimens have improved, resulting in enhanced graft and patient survival. At present, the side effects of immunosuppressive agents are a significant threat to post-LT quality of life and long-term outcome. The role of personalized immunosuppression is to reach a delicate balance between optimal immunosuppression and minimal side effects. Today, immunosuppression in LT is more of an art than a science. There are no validated markers for overimmunosuppression and underimmunosuppression, only a few drugs have therapeutic drug monitoring and immunosuppression regimens vary from center to center. The immunosuppressive agents are broadly classified into biological agents and pharmacological agents. Most regimens use multiple agents with different modes of action to reduce the dosage and minimize the toxicities. The calcineurin inhibitor (CNI)-related toxicities are reduced by antibody induction or using mTOR inhibitor/antimetabolites as CNI sparing or CNI minimization strategies. Post-liver transplant immunosuppression has an intensive phase in the first three months when alloreactivity is high, followed by a maintenance phase when immunosuppression minimization protocols are implemented. Over time some patients achieve "tolerance," defined as the successful stopping of immunosuppression with good graft function and no indication of rejection. Cell-based therapy using immune cells with tolerogenic potential is the future and may permit complete withdrawal of immunosuppressive agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.